Chronic HCV infection is a risk factor of ischemic stroke

Atherosclerosis

Volumn 231, Issue 1, 2013, Pages 22-26

  Adinolfi, Luigi E ^a   Restivo, Luciano ^a   Guerrera, Barbara ^a   Sellitto, Ausilio ^a   Ciervo, Antonella ^a   Iuliano, Natalina ^a   Rinaldi, Luca ^a   Santoro, Aldo ^a   Li Vigni, Giovanni ^a   Marrone, Aldo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Atherosclerosis; HCV; Ischemic heart disease; Ischemic stroke

Indexed keywords

CHOLESTEROL; FIBRINOGEN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEPATITIS C; HUMAN; ISCHEMIC HEART DISEASE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE PATIENT; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; HCV; ISCHEMIC HEART DISEASE; ISCHEMIC STROKE;

AGED; AGED, 80 AND OVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; ITALY; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; STROKE;

EID: 84885350780     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.003     Document Type: Article

References (33)

1. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000, 20:1-16.
2. Khattab M.A., Eslam M., Alavian S.M. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat Mon 2010, 10:258-269.
3. Durante-Mangoni E., Iardino P., Resse M., et al. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. JClin Gastroenterol 2004, 38:901-905.
4. Lonardo A., Adinolfi L.E., Loria P., et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004, 126:586-597.
5. Ishizaka N., Ishizaka Y., Takahashi E., et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002, 359:133-135.
6. Vassalle C., Masini S., Bianchi F., et al. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004, 90:565-566.
7. Boddi M., Abbate R., Chellini B., et al. Hepatitis C virus RNA localization in human carotid plaques. JClin Virol 2010, 47:72-75.
8. Adinolfi L.E., Restivo L., Zampino R., et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012, 221:496-502.
9. Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:577-617.
10. Nieto F.J. Infections and atherosclerosis: new clues from an old hypothesis?. Am J Epidemiol 1998, 148:937-948.
11. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
12. Lee M.H., Yang H.I., Wang C.H., et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010, 41:2894-2900.
13. Adinolfi L.E., Ingrosso D., Cesaro G., et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005, 41:995-1003.
14. Durante-Mangoni E., Zampino R., Marrone A., et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006, 24:1349-1357.
15. Vidali M., Tripodi M.F., Ivaldi A., et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. JHepatol 2008, 48:399-406.
16. Jonsson J.R., Barrie H.D., O'Rourke P., et al. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008, 48:80-87.
17. Adinolfi L.E., Restivo L., Zampino R., et al. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother 2011, 12:2215-2234.
18. Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006, 37:1923-1932.
19. Lonardo A., Lombardini S., Scaglioni F., et al. Hepatic steatosis and insulin resistance: does etiology make a difference?. JHepatol 2006, 44:190-196.
20. Vivona N., Bivona G., Noto D., et al. C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients. Clin Biochem 2009, 42:1713-1718.
21. Fletcher N.F., Wilson G.K., Murray J., et al. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 2012, 142:634-643.
22. Forde K.A., Haynes K., Troxel A.B., et al. Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. JViral Hepat 2012, 19:271-277.
23. Arcari C.M., Nelson K.E., Netski D.M., et al. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006, 43:53-56.
24. Cornberg M., Razavi H.A., Alberti A., et al. Asystematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011, 31:30-60.
25. GOLD Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2011 2011, Available from:. http://wwwgoldcopdorg/.
26. Liao C.C., Su T.C., Sung F.C., et al. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One 2012, 7:e31527.
27. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEngl J Med 2005, 352:1685-1695.
28. Oliveira C.P., Kappel C.R., Siqueira E.R., et al. Effect of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol 2011, Jul 22, [Epub ahead of print].
29. Antonelli A., Ferri C., Ferrari S.M., et al. High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-a in mixed cryoglobulinemia. World J Gastroenterol 2009, 15:5074-5079.
30. Giannakoulas G., Hatzitolios A., Karvounis H., et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology 2005, 56:723-730.
31. Ghany M.G., Strader D.B., Thomas D.L., et al. American association for the study of liver diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
32. EASL clinical practice guidelines: management of hepatitis C virus infection. JHepatol 2011, 55:245-264.
33. Hsu C.-S., Kao J.H., Chao Y.C., et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population- based cohort study in taiwan. Aliment Pharmacol Ther 2013, 38:415-423.